Answers are grounded in this paper and cite their sources.
Background Postherpetic neuralgia (PHN) is a debilitating complication of herpes zoster. Evidence supporting pulsed radiofrequency (PRF) in established chronic PHN remains limited, with inadequate adjustment for baseline confounders. We evaluated the association between PRF and treatment success and identified predictors of treatment response. Methods In this retrospective cohort study, 982 patients with PHN (pain persisting ≥ 12 weeks after rash onset) were analyzed. Patients who underwent PRF (n = 504)—targeting the dorsal root ganglion, the Gasserian ganglion, or involved peripheral nerves—were compared with controls who did not undergo PRF at any time during the study period and who received standard pharmacological and non-PRF interventional management (n = 478). Propensity score-based overlap weighting (ATO) balanced 29 baseline covariates. The primary outcome was treatment success at 12 weeks (≥ 2-point reduction on the 11-point numeric rating scale (NRS)). Effects were estimated using doubly robust estimation. Results After ATO adjustment, all covariates achieved adequate balance (standardized mean differences < 0.1). Treatment success at 12 weeks was 63.0% (PRF) versus 52.1% (control; doubly robust OR, 1.59; 95% CI, 1.12–2.25; P = .009). Greater mean pain reduction was observed at 4 weeks (P = .040) but not sustained thereafter. Exploratory subgroup analyses suggested PRF was more effective in patients with dysesthesia, without allodynia, and not receiving pregabalin or tramadol. Conclusions PRF provides clinically meaningful, albeit time-limited, pain reduction in PHN patients. Exploratory findings suggest that treatment response may vary according to sensory phenotype and pharmacological profile, underscoring the importance of profile-guided patient selection.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: